BTIG Maintains Buy on Guardant Health, Raises Price Target to $190
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ: GH ) with a Buy and raises the price target from $160 to $190.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.